BioNTech Shares Surge in 2026 as Analysts See Further Upside

BioNTech shares have started 2026 with impressive momentum, standing out as one of the stronger performers in the European biotech space. In XETRA trading, the biotech stock is already up 21.57 percent since the beginning of the year. Against that backdrop, a brief pullback on Monday—when shares dipped by 0.80 percent to €98.90—appears largely insignificant and does little to dent the broader positive trend.

The upbeat picture is mirrored in the U.S. market. BioNTech’s American Depositary Receipts (ADRs), traded on the NASDAQ, have gained 21.83 percent year to date. Investor enthusiasm remains intact, with the shares adding another 1.11 percent in pre-market trading to reach $117.27. Taken together, the performance on both sides of the Atlantic highlights renewed confidence in the company after a comparatively muted prior year.

BioNTech Shares Rally Strongly in 2026

Analysts, meanwhile, remain firmly optimistic. Experts at private bank Berenberg see substantial upside still ahead. The analyst team led by Sam England has reiterated its “buy” recommendation and maintained a price target of $155. According to Berenberg, BioNTech continues to offer notable catch-up potential following an underwhelming performance in the previous year, suggesting that the recent rally may not yet be over.

The broader sector context adds nuance to this outlook. In an industry study published on Friday, analysts described 2025 as another mixed year for the medical technology and life sciences sector. Share prices were weighed down by U.S. policy decisions, ongoing weakness in the Chinese market, and overall macroeconomic softness.

While many of these headwinds are expected to persist in 2026, early signs of recovery are beginning to emerge—particularly within life sciences. Importantly, valuations across the sector remain at multi-year lows, creating attractive medium-term opportunities for investors willing to look beyond near-term uncertainty.

BioNTech’s evolving business focus also plays a key role in the investment case. The Mainz-based biotechnology company rose to global prominence through its mRNA technology and the COVID-19 vaccine BNT162b2, developed in partnership with Pfizer. Today, however, attention is increasingly shifting toward oncology, immunotherapies, and next-generation mRNA-based treatments targeting cancer and infectious diseases.

Market sentiment reflects this strategic pivot. On TipRanks, 15 analysts currently cover the stock: 13 recommend buying, while two suggest holding. The average price target stands at $143.50—well above current levels, though still below Berenberg’s more bullish forecast. Overall, the message is clear: many experts believe BioNTech’s best days in 2026 may still lie ahead.

__

(Featured image by Yorgos Ntrahas via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in finanzen.net. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.